Abstract
Inosine 5-monophosphate dehydrogenase (IMPDH) catalyzes the first committed step of guanosine 5-monophosphate (GMP) biosynthesis, and thus regulates the guanine nucleotide pool, which in turn governs proliferation. Human IMPDHs are validated targets for immunosuppressive, antiviral and anticancer drugs, but as yet microbial IMPDHs have not been exploited in antimicrobial chemotherapy. Selective inhibitors of IMPDH from Cryptosporidium parvum have recently been discovered that display anti-parasitic activity in cell culture models of infection. X-ray crystal structure and mutagenesis experiments identified the structural features that determine inhibitor susceptibility. These features are found in IMPDHs from a wide variety of pathogenic bacteria, including select agents and multiply drug resistant strains. A second generation inhibitor displays antibacterial activity against Helicobacter pylori, demonstrating the antibiotic potential of IMPDH inhibitors.
Keywords: Antibacterial, Cryptosporidium parvum, guanine nucleotide, biosynthesis, Helicobacter pylori, IMPDH, inosine 5'- monophosphate dehydrogenase, select agents, Mycobacterium tuberculosis
Current Medicinal Chemistry
Title: The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors
Volume: 18 Issue: 13
Author(s): L. Hedstrom, G. Liechti, J. B. Goldberg and D. R. Gollapalli
Affiliation:
Keywords: Antibacterial, Cryptosporidium parvum, guanine nucleotide, biosynthesis, Helicobacter pylori, IMPDH, inosine 5'- monophosphate dehydrogenase, select agents, Mycobacterium tuberculosis
Abstract: Inosine 5-monophosphate dehydrogenase (IMPDH) catalyzes the first committed step of guanosine 5-monophosphate (GMP) biosynthesis, and thus regulates the guanine nucleotide pool, which in turn governs proliferation. Human IMPDHs are validated targets for immunosuppressive, antiviral and anticancer drugs, but as yet microbial IMPDHs have not been exploited in antimicrobial chemotherapy. Selective inhibitors of IMPDH from Cryptosporidium parvum have recently been discovered that display anti-parasitic activity in cell culture models of infection. X-ray crystal structure and mutagenesis experiments identified the structural features that determine inhibitor susceptibility. These features are found in IMPDHs from a wide variety of pathogenic bacteria, including select agents and multiply drug resistant strains. A second generation inhibitor displays antibacterial activity against Helicobacter pylori, demonstrating the antibiotic potential of IMPDH inhibitors.
Export Options
About this article
Cite this article as:
Hedstrom L., Liechti G., B. Goldberg J. and R. Gollapalli D., The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors, Current Medicinal Chemistry 2011; 18 (13) . https://dx.doi.org/10.2174/092986711795590129
DOI https://dx.doi.org/10.2174/092986711795590129 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Group A Streptococcal Infections in Children
Current Pediatric Reviews Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets West Nile Virus Vaccine.
Current Drug Targets - Infectious Disorders Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews Therapeutic Application of Melatonin in the Treatment of Melanoma: A Review
Current Cancer Therapy Reviews The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Conference Report: (Annual Advances in Neurorestoratology: A Summary of IANR VI and 10th GCNN Conference, Bucharest, Romania, April 4-7, 2013)
CNS & Neurological Disorders - Drug Targets Mechanisms of Neuronal Damage and Neuroprotection Underlying Ischemia/Reperfusion Injury after Physical Exercise
Current Drug Targets New Missions for an Old Agent: Granulocyte-Colony Stimulating Factor in the Treatment of Stroke Patients
Current Medicinal Chemistry Monoclonal Antibodies in the Treatment of Leukemia
Current Molecular Medicine The Journey of the Non-Vascular Relief for Migraine: From ‘Triptans’ To ‘Ditans’
Current Clinical Pharmacology Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets What we have Learned from Animal Models of Mycoplasma pneumoniae Disease: Virulence Mechanisms and Host Responses
Current Pediatric Reviews Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Perineural Invasion in Adenoid Cystic Carcinoma of the Salivary Glands: Anatomical Influences on Oncological Management
Current Cancer Therapy Reviews Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Medication Conveyance Through Nose: Factors Affecting and Novel Applications
Drug Delivery Letters Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets Diagnostic Value of the Leukocyte Esterase Test for Early Detection of Pleocytosis in Cerebrospinal Fluid of Patients with Suspected Acute Bacterial Meningitis
Infectious Disorders - Drug Targets